Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double-blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia-free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of "Asleep" time throughout the study. No apparent differences were detected in the occurrence of drug-related adverse events between the Zydis selegiline group and placebo-treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.20036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Neuropsychopharmacology
February 2015
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Article Synopsis
- Selegiline (L-deprenyl) is primarily used to treat Parkinson's disease as a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at standard doses, but higher doses show potential antidepressant effects by possibly inhibiting MAO-A as well.
- Zydis selegiline (Zelapar) is a fast-dissolving version that allows for better absorption, leading to increased plasma levels and fewer metabolite effects compared to regular selegiline; however, its selectivity for MAO-B may diminish at higher dosages.
- A study found that a 10 mg daily dose of Zydis selegiline significantly inhibited MAO-A in healthy men, providing the first direct
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.
Parkinsonism Relat Disord
February 2011
Dept. of Neurology, Baylor college of Medicine, 6550 Fannin, Ste 1801, Houston, TX 77030, USA.
Selegiline is a monoamine-B specific inhibitor used to treat Parkinson's disease. A Zydis sublingual preparation has more efficient absorption and less first pass amphetamine metabolites. We conducted an open label oral to Zydis switch study to evaluate tolerability of rapid switch, and relative efficacy, in 48 subjects from 5 sites.
View Article and Find Full Text PDFZydis selegiline in the management of Parkinson's disease.
Expert Opin Pharmacother
October 2007
Columbia University Medical Center, Department of Neurology, Division of Movement Disorders, 710 W. 168th Street, New York, NY 10032, USA.
Selegiline, a selective monoamine oxidase-B inhibitor, has been used for decades in the treatment of Parkinson's disease. The recent development of an orally disintegrating dosage form using Zydis technology allows pregastric drug absorption and, thus, greatly improving the pharmacodynamic and pharmacokinetic drug profiles. This new formulation provides higher drug bioavailability and a substantially reduced concentration of active metabolites.
View Article and Find Full Text PDFMonamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Clin Neuropharmacol
August 2007
Movement Disorders Center, Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, FL 32610, USA.
Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, for the symptomatic treatment of Parkinson disease (PD).
View Article and Find Full Text PDFObjective: Patients receiving levodopa for Parkinson's disease experience motor fluctuations and immobility ('off' episodes) between doses. This study assessed adjunctive Zelapar (selegiline orally disintegrating tablet (ODT)) for managing off episodes and for long-term safety.
Methods: This open-label extension evaluated long-term safety, efficacy, and tolerability of adjunctive selegiline ODT 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!